Answers are grounded in this paper and cite their sources.
Demonstrates improved interpretation of histopathology metrics in neoadjuvant oncology, suggesting better prognostic insights.
Neoadjuvant therapy is expanding rapidly across tumor types, yet efficacy endpoints remain anchored in subjective tumor regression grading systems developed for cytotoxic therapy. We argue that post-treatment histopathology should evolve toward quantitative and biologically interpretable metrics integrating tumor burden, immune contexture, and spatial organization. We outline a validation pathway distinguishing prognostic biomarkers from true surrogate endpoints and propose a tumor- and regimen-aware framework for developing reproducible histologic endpoints in neoadjuvant oncology.
No takes yet. Share an insight, caveat, or question.
Schraepen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: